Halometasone

DB13728InvestigationalSmall molecule

Halometasone is a corticosteroid indicated in the treatment of corticosteroid responsive dermatoses. A medication used to treat skin conditions with inflammation.

Mechanism: Pharmacologically active on Glucocorticoid receptor
Curator reviewed
Formula / weight: C₂₂H₂₇ClF₂O₅ · 444.9 g/mol (avg)

Resolves to

Compound

UNIIJ69Z9UU41ZCAS50629-82-8ChEMBLCHEMBL1587228ChEBI135724

Clinical / RWD

RxNorm26416ATCD07AC12

Structure

InChIKeyGGXMRPUKBWXVHE-MIHLVHIWSA-NSMILESC[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C(Cl)=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO

Targets

P04150NR3C1

What you can answer from here — as of July 10, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

141Drug interactionsStructured to mechanism, not free text

2Clinical trialsPhase, status and sponsor resolved per trial

1Structured indicationCondition, population, route and combination as fields, not prose

14ContraindicationsEach with its own population and attribute set

3Marketed productsAcross 1 country and 2 labellers

1ATC codeIncluding every combination product, plus 22 drug categories

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with Halometasone, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account